Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Arcus Biosciences revenue
Arcus Biosciences's revenue is $258.0 million.
What is Arcus Biosciences's revenue?
- Arcus Biosciences's revenue growth from 2017 to 2024 is 18,159.02%.
- Arcus Biosciences has 236 employees, and the revenue per employee ratio is $1,093,220.
- Arcus Biosciences's peak quarterly revenue was $26.0M in 2024(q4).
- Arcus Biosciences peak revenue was $383.0M in 2021.
- Arcus Biosciences annual revenue for 2023 was 117.0M, 4.46% growth from 2022.
- Arcus Biosciences annual revenue for 2024 was 258.0M, 120.51% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Arcus Biosciences historical revenue
Arcus Biosciences's peak revenue was $383.0M in 2021. The peak quarterly revenue was $26.0M in 2024(q4).
Arcus Biosciences's revenue increased from $1.4m in 2017 to $258.0M currently. That's a 18,159.02% change in annual revenue.
Arcus Biosciences annual revenue
Arcus Biosciences annual revenue over time
| Fiscal year / year | Arcus Biosciences revenue |
|---|---|
| 2017 | $1.4M |
| 2018 | $8.4M |
| 2019 | $15.0M |
| 2020 | $78.0M |
| 2021 | $383.0M |
| 2022 | $112.0M |
| 2023 | $117.0M |
| 2024 | $258.0M |
Rate Arcus Biosciences' financial transparency
Arcus Biosciences annual growth
Arcus Biosciences saw the greatest revenue growth in 2018, when revenue increased by 491.15%.
Arcus Biosciences had the lowest revenue growth in 2022, when revenue changed by -70.76%.
Arcus Biosciences annual growth rate over time
| Year | Arcus Biosciences growth |
|---|---|
| 2018 | 491%↑ |
| 2019 | 80%↑ |
| 2020 | 420%↑ |
| 2021 | 391%↑ |
| 2022 | -71%↓ |
| 2023 | 4%↑ |
| 2024 | 121%↑ |
Arcus Biosciences jobs nearby
Do you work at Arcus Biosciences?
Is Arcus Biosciences transparent about its revenue structure?
Arcus Biosciences financial information
| CEO | Terry J. Rosen |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 236 |
| Date Founded | 2015 |
| Headquarters | Hayward, California |
| Revenue | $258.0M |
| Net Income | -$263,000,000 |
| Tax Rate | -0.0% |
| Total Assets | $1,345,000,000 |
| Ticker | RCUS |
Arcus Biosciences jobs you might like
Arcus Biosciences financing
Arcus Biosciences received early financing of $49.7M on 2015-05-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $49.7M | 05/2015 |
| Series B | $70M | 09/2016 |
| Series C | $107M | 11/2017 |
| Post Ipo Equity | $200M | 05/2020 |
| Post Ipo Equity | $220.4M | 02/2021 |
Arcus Biosciences investors
| Investors | Security type |
|---|---|
| CELGENE CORP /DE/ | Series A |
| The Column Group | Series A |
| Novartis | Series B |
| CELGENE CORP /DE/ | Series B |
| Invus | Series B |
| Stanford University | Series B |
| DROIA Ventures | Series B |
| Taiho Ventures LLC | Series B |
| RTA CAPITAL LLC | Series B |
| Foresite Capital | Series B |
| GV | Series B |
| The Column Group | Series B |
| EcoR1 Capital, LLC | Series C |
| CELGENE CORP /DE/ | Series C |
| Decheng Capital | Series C |
| Hillhouse Capital Group | Series C |
| Biotechnology Value Fund | Series C |
| The Column Group | Series C |
| Aisling Capital | Series C |
| Invus | Series C |
| Wellington Management | Series C |
| DROIA Ventures | Series C |
| Taiho Ventures LLC | Series C |
| Foresite Capital | Series C |
| Leerink Partners LLC | Series C |
| GV | Series C |
| Gilead Sciences, Inc. | Post Ipo Equity |
| Gilead Sciences, Inc. | Post Ipo Equity |
Arcus Biosciences competitors
Arcus Biosciences's top competitor, Axsome Therapeutics, earned an annual revenue of $385.7M.
Arcus Biosciences's smallest competitor is Edgewise Therapeutics with revenue of $30.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Edgewise Therapeutics | - | $30,000 | 45 | - |
| Leap Therapeutics | - | $1.5M | 30 | - |
| Prelude Therapeutics | - | $7.0M | 70 | - |
| MabVax Therapeutics | - | $1.6M | 11 | - |
| Bird Rock Bio | - | $5.0M | 3 | - |
| Nurix | - | $54.5M | 103 | - |
| Allos Therapeutics | - | $76.0M | 175 | - |
| Axsome Therapeutics | - | $385.7M | 29 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Cerecor | - | $6.7M | 32 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Arcus Biosciences highest paying jobs
Zippia gives an in-depth look into the details of Arcus Biosciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Arcus Biosciences. The employee data is based on information from people who have self-reported their past or current employments at Arcus Biosciences. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Arcus Biosciences. The data presented on this page does not represent the view of Arcus Biosciences and its employees or that of Zippia.
Arcus Biosciences may also be known as or be related to ARCUS BIOSCIENCES, INC., Arcus Biosciences, Arcus Biosciences Inc and Arcus Biosciences, Inc.